Assessment of therapeutic response in ankylosing spondylitis patients undergoing anti-tumour necrosis factor therapy by whole-body magnetic resonance imaging

European Radiology

Volumn 23, Issue 7, 2013, Pages 1773-1784

  Karpitschka, Martina ^a   Godau Kellner, Patrizia ^b   Kellner, Herbert ^b   Horng, Annie ^a   Theisen, Daniel ^a   Glaser, Christian ^c   Brandlhuber, Bernhard ^a   Reiser, Maximilian ^a   Weckbach, Sabine ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Praxis für Rheumatologie ^*  (Germany)

^c RZM Zentrum   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Anti inflammatory agents; Gadolinium; Magnetic resonance imaging; Spondylitis, ankylosing; Whole body imaging

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GADOLINIUM PENTETATE MEGLUMINE; HLA B27 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE DURATION; DRUG TREATMENT FAILURE; ENTHESITIS; FAMILY HISTORY; FEMALE; HUMAN; IMAGE ANALYSIS; LOW BACK PAIN; MALE; MORNING STIFFNESS; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RATING SCALE; REPEAT PROCEDURE; SACROILIAC JOINT; SACROILIITIS; SCANNING ELECTRON MICROSCOPY; SYNOVITIS; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; WHOLE BODY IMAGING; WHOLE BODY MRI;

ADULT; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; SYNOVITIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WHOLE BODY IMAGING;

EID: 84879026994     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-013-2794-1     Document Type: Article

References (41)

1. Marzo-Ortega H, McGonagle D, O'Connor P, Hensor EM, Bennett AN, Green MJ (2009) Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. Ann Rheum Dis 68:1721-1727
2. Boonen A, Chorus A, Midema H, van der Heijde D, van der Tempel H, van der Linden S (2001) Employment, work disability and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60:353-358
3. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
4. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W (1988) Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 15:1109-1114
5. Braun J, Bollow M, Remlinger G et al (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58-67
6. Ory PA, Gladman DD, Mease PJ (2005) Psoriatic arthritis and imaging. Ann Rheum Dis 64:ii55-ii57
7. Bollow M, Fischer T, Reisshauer H et al (2000) Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis - cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 59:135-140
8. Bennett AN, McGonagle D, O'Connor P, Hensor EM, Sivera F, Coates LC (2008) Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 58:3413-3418
9. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J (2009) The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777-783
10. Weber U, Pfirrmann CW, Kissling RO, Hodler J, Zanetti M (2007) Whole body MR imaging ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis. BMC Musculoskelet Disord 8:20
11. Weckbach S (2009) Whole-body MR imaging for patients with rheumatism. Eur J Radiol 70:431-441
12. Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I (2005) Nonsteroidal anti inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52:1756-1765
13. National Institute for Health and Clinical Excellence (2008) Adalimumab, Etanercept and Infliximab for Ankylosing Spondylitis. NICE, London. Available via http://guidance.nice.org.uk/TA143
14. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442-452
15. Braun J, Deodhar A, Dijkmans B et al (2008) Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 59:1270-1278
16. Dijkmans B, Emery P, Hakala M et al (2009) Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 36:1256-1264
17. van der Heijde D, Schiff MH, Sieper J et al (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 68:922-929
18. Calin A, Garrel S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol 21:2281-2285
19. Garrett S, Ienkinson T, Kennedy G, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286-2291
20. Van der Heijde D, Dougados M, Davis J et al (2005) Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendation for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 52:386-394
21. Van der Heijde D, Calin A, Dougados M et al (1999) Selection of instruments in the core set for DC-ART, SMARD, physical therapy and clinical record keeping in ankylosing spondylitis: progress report of the ASAS Working Group. J Rheumatol 26:951-954
22. Sheehan NJ, Slavin BM, Donovan MP, Mount JN, Mathews JA (1986) Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 25:171-174
23. Lin Z, Gu J, He P et al (2001) Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients. Rheumatol Int 31:233-238
24. Barkham N, Keen HI, Coates LC et al (2009) Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60:946-954
25. Braun J, Landewe R, Hermann KG et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54:1646-1652
26. Althoff CE, Appel H, Rudwaleit M et al (2007) Whole-body MRI as a new screening tool for detecting axial and peripheral manifestations of spondyloarthritis. Ann Rheum Dis 66:983-985
27. Appel H, Hermann KG, Althoff CE, Rudwaleit M, Sieper J (2007) Whole-body magnetic resonance imaging evaluation of widespread inflammatory lesions in a patient with ankylosing spondylitis before and after 1 year of treatment with infliximab. J Rheumatol 34:2497-2498
28. Calin A, Porta J, Fries JF, Schurmann DJ (2009) Clinical history as a screening test for ankylosing spondylitis. JAMA 237:2613-2614
29. Rudwaleit M, Jurik AG, Hermann KG et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68:1520-1527
30. Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218-1227
31. Hermann KG, Braun J, Fischer T, Reisshauer H, Bollow M (2004) Magnetic resonance tomography of sacroiliitis: anatomy, histological pathology, MR-morphology, and grading]. Radiologe 44:217-228
32. Maksymowych WP, Crowther SM, Dhillon SS, Conner-Spady B, Lambert RG (2010) Systematic assessment of inflammation by magnetic resonance imaging in the posterior elements of the spine in ankylosing spondylitis. Arthritis Care Res 62:4-10
33. Bochkova AG, Levshakova AV, Bunchuk NV, Braun J (2010) Spinal inflammation lesions as detected by magnetic resonance imaging in patients with early ankylosing spondylitis are more often observed in posterior structures of the spine. Rheumatology 49:749-755
34. Song IH, Hermann K, Haibel H et al (2011) Effects of etanercept versus sulfalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 70:590-596
35. Dougados M, Combe B, Braun J et al (2010) A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 69:1430-1435
36. McGonagle D, Marzo-Ortega H, O'Connor P et al (2002) Histological assessment of the early enthesitis lesion in spondyloarthropathy. Ann Rheum Dis 61:534-537
37. Maksymowych WP (2000) Ankylosing spondylitis - at the interface of bone and cartilage. J Rheumatol 27:2295-2301
38. Emery P, Breedveld FC, Hall S et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372:375-382
39. Sieper J, Appel H, Braun J, Rudwaleit M (2008) Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 58:649-656
40. Rudwaleit M, Listing J, Brandt J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63:665-670
41. Rudwaleit M, Claudepierre P, Wordsworth P et al (2009) Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 36:801-808